Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amylyx PharmaceuticalsAMLX -5.70%28 3-Year EBITDA Growth Rate is 22.20% as of Jun. 2026. GuruFocus rates AMLX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 811 Drug Manufacturers companies, Amylyx Pharmaceuticals ranks better than 71.76% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Amylyx Pharmaceuticals was 22.20% per year. The lowest was -132.60% per year. And the median was -35.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Amylyx Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
AMLX vs ANIP, PBH, BCRX: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Amylyx Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amylyx Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amylyx Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.20% mean?
Amylyx Pharmaceuticals (AMLX) has a 3-Year EBITDA Growth Rate of 22.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amylyx Pharmaceuticals and its competitors. According to the industry distribution chart, Amylyx Pharmaceuticals ranks #229 out of 811 companies in the Drug Manufacturers industry, placing it in the top 28.2%.
Is Amylyx Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
Amylyx Pharmaceuticals' current 3-Year EBITDA Growth Rate is 22.20%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Amylyx Pharmaceuticals' value of 22.20% is 152.3% above this industry median. Based on the distribution chart, Amylyx Pharmaceuticals ranks #229 out of 811 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amylyx Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Amylyx Pharmaceuticals' 3-Year EBITDA Growth Rate compare to ANIP and PBH?
According to the Drug Manufacturers industry distribution chart, Amylyx Pharmaceuticals ranks #229 out of 811 companies for 3-Year EBITDA Growth Rate. This puts Amylyx Pharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. Amylyx Pharmaceuticals' value of 22.20% is 152.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amylyx Pharmaceuticals's current 3-Year EBITDA Growth Rate of 22.20% is 152.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Amylyx Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amylyx Pharmaceuticals's current 3-Year EBITDA Growth Rate is 22.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amylyx Pharmaceuticals stock overvalued right now?
Amylyx Pharmaceuticals (AMLX) has a current 3-Year EBITDA Growth Rate of 22.20%. The current 3-Year EBITDA Growth Rate is 22.20% and 152.3% above the Drug Manufacturers industry median of 8.80. Amylyx Pharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Amylyx Pharmaceuticals (AMLX), the current 3-Year EBITDA Growth Rate is 22.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.
28GF Score
Get the complete analysis for AMLX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AMLX has been successfully added to your 
